DHH Successfully Advised Two Major Special Services of Changjin Biotech: Pre A Round of Financing and the First Phase of Equity Incentive
Release time：2022-05-05 09:26
Recently, the risk control investment bank team of Beijing DHH Law Firm assisted Shanghai Changjin Biotech Co., Ltd. (hereinafter referred to as "Changjin Biotech"), a leading enterprise in edible microbial protein synthesis, to complete the Pre-A round of financing. While assisting Changjin Biotech to complete the first round of financing, the risk control investment bank team also tailored and completed the full implementation of the first phase of equity incentive plan for Changjin Biotech according to its development stage, the company's development goals, and the concept of entrepreneurship and innovation.